Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1616-1618

  Belser, Jessica A ^a   Sleeman, Katrina ^a   Pearce, Melissa B ^a   Katz, Jacqueline M ^a   Gubareva, Larisa V ^a   Tumpey, Terrence M ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; INFLUENZA; INFLUENZA VIRUS A H7N3; INFLUENZA VIRUS A H7N7; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL EYE INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CONJUNCTIVITIS; EYE; HUMANS; INFLUENZA A VIRUS, H7N3 SUBTYPE; INFLUENZA A VIRUS, H7N7 SUBTYPE; INFLUENZA, HUMAN; INJECTIONS, INTRAOCULAR; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; VIRAL PROTEINS; VIRUS REPLICATION; VISION, OCULAR;

EID: 84857148366     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06101-11     Document Type: Article

References (27)

1. Banks J, Speidel EC, McCauley JW, Alexander DJ. 2000. Phylogenetic analysis of H7 haemagglutinin subtype influenza A viruses. Arch. Virol. 145:1047-1058. (Pubitemid 30333947)
2. Belser JA, et al. 2008. Contemporary North American influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. Proc. Natl. Acad. Sci. U. S. A. 105:7558 -7563.
3. Belser JA, Bridges CB, Katz JM, Tumpey TM. 2009. Past, present, and possible future human infection with influenza virus A subtype H7. Emerg. Infect. Dis. 15:859-865.
4. Belser JA, et al. 2007. Pathogenesis of avian influenza (H7) virus infection in mice and ferrets: enhanced virulence of Eurasian H7N7 viruses isolated from humans. J. Virol. 81:11139 -11147.
5. Belser JA, Wadford DA, Xu J, Katz JM, Tumpey TM. 2009. Ocular infection of mice with influenza A (H7) viruses: a site of primary replication and spread to the respiratory tract. J. Virol. 83:7075-7084.
6. Belser JA, Zeng H, Katz JM, Tumpey TM. 2011. Infection with highly pathogenic H7 influenza viruses results in an attenuated proinflammatory cytokine and chemokine response early after infection. J. Infect. Dis. 203: 40-48.
7. CDC. 20 September 2010, posting date. Guidelines and recommendations: prevention strategies for seasonal influenza in healthcare settings. Centers for Disease Control and Prevention, Atlanta, GA.
8. CDC. 14 January 2006, posting date. Interim guidance for protection of persons involved in U.S. avian influenza outbreak disease control and eradication activities. Centers for Disease Control and Prevention, Atlanta, GA.
9. Eames KT, et al. 2010. Assessing the role of contact tracing in a suspected H7N2 influenza A outbreak in humans in Wales.BMCInfect. Dis. 10:141.
10. Fouchier RA, et al. 2004. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. U. S. A. 101:1356-1361. (Pubitemid 38182693)
11. Gubareva LV, Kaiser L, Hayden FG. 2000. Influenza virus neuraminidase inhibitors. Lancet 355:827-835. (Pubitemid 30128828)
12. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
13. Gubareva LV, Penn CR, Webster RG. 1995. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4- dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 212:323-330.
14. Ilyushina NA, Govorkova EA, Russell CJ, Hoffmann E, Webster RG. 2007. Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. J. Gen. Virol. 88:1266-1274. (Pubitemid 46523516)
15. Joseph T, et al. 2007. Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J. Virol. 81:10558-10566. (Pubitemid 47463329)
16. Koopmans M, et al. 2004. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363:587-593. (Pubitemid 38264175)
17. Morgan O, et al. 2009. Personal protective equipment and risk for avian influenza (H7N3). Emerg. Infect. Dis. 15:59-62.
18. Nguyen HT, Sheu TG, Mishin VP, Klimov AL, Gubareva LV. 2010. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 54:3671-3677.
19. Sheu TG, et al. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292.
20. Skowronski DM, et al. 2007. Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada. CMAJ 176:47-53. (Pubitemid 46144743)
21. Sleeman K, et al. 2010. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 54:2517-2524.
22. te Beest DE, van Boven M, Bos ME, Stegeman A, Koopmans MP. 2010. Effectiveness of personal protective equipment and oseltamivir prophylaxis during avian influenza A (H7N7) epidemic, the Netherlands, 2003. Emerg. Infect. Dis. 16:1562-1568.
23. Tisdale M. 2000. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55. (Pubitemid 30103133)
24. Tumpey TM, et al. 2002. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. Sci. U. S. A. 99:13849-13854. (Pubitemid 35215469)
25. Tweed SA, et al. 2004. Human illness from avian influenza H7N3, British Columbia. Emerg. Infect. Dis. 10:2196 -2199.
26. Woods JM, et al. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N- acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1473-1479. (Pubitemid 23202375)
27. Yen HL, Monto AS, Webster RG, Govorkova EA. 2005. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 192:665-672.